JBIO NASDAQ
Jade Biosciences, Inc.
1W: -2.8%
1M: -7.6%
3M: +64.4%
YTD: +65.7%
1Y: +203.9%
$22.21
-1.25 (-5.33%)
Weekly Expected Move ±12.7%
$17
$20
$23
$26
$29
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$724.6M
52W Range6.565-28
Volume367,230
Avg Volume568,226
Beta1.52
Dividend$2.40
Analyst Ratings
Company Info
CEOTom Frohlich
Employees50
SectorHealthcare
IndustryBiotechnology
IPO Date2025-04-29
Websitejadebiosciences.com
221 Crescent Street Building 23
Waltham, MA 02453
US
Waltham, MA 02453
US
1 916-322-1700
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Latest News
Jade Biosciences, Inc. GAAP EPS of -$0.57 misses by $0.09
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
867,284 Shares in Jade Biosciences, Inc. $JBIO Bought by Aberdeen Group plc
Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Rating of “Moderate Buy” by Brokerages
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dahms Bradford D. | A-Award | 226,875 | $14.81 | 2026-02-12 |
| Dahms Bradford D. | A-Award | 37,813 | — | 2026-02-12 |
| Balta Elizabeth | A-Award | 168,750 | $14.81 | 2026-02-12 |
| Balta Elizabeth | A-Award | 28,125 | — | 2026-02-12 |
| Frohlich Tom | A-Award | 472,500 | $14.81 | 2026-02-12 |